- Else (BABY) has received Institutional Review Board (IRB) approval for its infant growth clinical study protocol
- This is a key step toward the U.S. launch of Else’s new plant-based infant formula, which will serve as an alternative to dairy and soy-based products
- CEO Hamutal Yitzhak spoke with Coreena Robertson about the news
- Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults
- Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share
Else Nutrition (BABY) has received IRB approval for its infant growth clinical study protocol.
The clinical study will provide vital insights into the formula’s effectiveness and safety for infants.
This is a critical step in the company’s plan to launch a new plant-based infant formula in the U.S. as an alternative to dairy and soy-based products.
CEO Hamutal Yitzhak spoke with Coreena Robertson about the news.
Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults.
Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share as of 9:44 am EST.